Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of an ophthalmology exam setting as Minghui Pharmaceutical’s MHB018A data sharpen interest in subcutaneous IGF-1R antibody therapy for thyroid eye disease.
Pharma & Biotech

Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?

Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.

Read More
Representative image of a doctor discussing needle-free allergy treatment with a child and caregiver, reflecting coverage of EURneffy 1 mg’s UK approval for pediatric anaphylaxis care.
Pharma & Biotech

Why EURneffy’s UK pediatric approval could change emergency allergy treatment for children

Find out how EURneffy 1 mg’s UK approval could change needle-free anaphylaxis treatment for young children today.

Read More
Representative image of blood testing in a clinical laboratory, reflecting coverage of Agios Pharmaceuticals’ mitapivat Phase 3 RISE UP data and the evolving sickle cell disease treatment debate.
Pharma & Biotech

Why mitapivat’s Phase 3 data could change the sickle cell disease treatment debate

Find out how Agios’ mitapivat Phase 3 data could shape the next treatment debate in sickle cell disease care.

Read More
Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.
Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

Read how Mirum and Incyte’s zilurgisertib Phase 2 data could reshape FOP treatment, FDA review risk and rare disease strategy.

Read More
Representative biotech patent litigation image showing antibody discovery research, laboratory documents and legal symbols.
Pharma & Biotech

Could Harbour BioMed’s legal win reshape the economics of antibody drug discovery?

Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.

Read More
Representative image of a clinical researcher reviewing liver imaging and lipid test results, reflecting OrsoBio’s TLC-2716 Phase 2a data in severe hypertriglyceridemia and MASLD.
Pharma & Biotech

OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease

Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.

Read More
Representative image of advanced CAR T-cell therapy research and infusion monitoring, reflecting CARsgen Therapeutics’ CT0596 and CT1190B data in multiple myeloma and B-cell lymphoma.
Pharma & Biotech

How CARsgen’s EHA 2026 data could change investor debate around allogeneic CAR T

Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.

Read More
Representative image of pharmaceutical regulatory documents and medicine, illustrating Xeris Biopharma’s Keveyis patent allowance and its potential impact on rare disease treatment exclusivity.
Pharma & Biotech

Xeris wins key Keveyis patent allowance, but will it really slow generic pressure?

Find out how Xeris’ Keveyis patent allowance could reshape rare disease exclusivity, generic pressure and investor sentiment.

Read More
Beekeeper’s Naturals recall shows why OTC nasal products face tougher trust tests
Pharma & Biotech

Amazon-sold Beekeeper’s Naturals nasal spray recall sharpens focus on contamination risk

Find out why Beekeeper’s Naturals’ nasal spray recall raises wider questions for OTC health brands, Amazon sales and quality control.

Read More
Representative image of neuropsychiatric drug research, as Otsuka Pharmaceutical’s Transcend Therapeutics acquisition puts TSND-201 and rapid-acting PTSD treatment innovation in focus.
Pharma & Biotech

Why Otsuka’s $1.2bn Transcend Therapeutics buyout could reshape PTSD drug development

Find out how Otsuka’s Transcend Therapeutics acquisition could reshape rapid-acting PTSD treatment development.

Read More